Article

Clinical Characteristics and Risk Factors for Persistent Thrombocytopenia among Pediatric Patients after Bone Marrow Transplant in Saudi Arabia: A 3-Year Retrospective Observational Analysis from Tertiary Hospital

Mohammed Kanan1★, Abdullah Almotairi2, Faisal Alrumaih3, Reem Hammad3, Mohammed Almotairi1★ Corresponding author

  1. 1Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, SAUDI ARABIA.
  2. 2Department of Clinical Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, SAUDI ARABIA.
  3. 3Department of Clinical Pharmacy, Northern Border University, Arar, SAUDI ARABIA.

CORRESPONDENCE

Mohammed Kanan

Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, SAUDI ARABIA.

ii_kanan101@outlook.com

Received: 27-08-2024; Revised: 13-10-2024; Accepted: 06-11-2024.

Volume 16, Issue 2 · pp. 214–225 · PUBLISHED 2025 · DOI: 10.1177/0976500X241303618

View on JPP original site ↗

ABSTRACT

Background: Bone marrow transplantation (BMT) is a crucial treatment for pediatric patients with various hematological, oncological, and genetic diseases. However, persistent thrombocytopenia (PT) post-transplantation poses a significant challenge, affecting recovery and prognosis. Objectives: This study aimed to identify the clinical characteristics and risk factors associated with PT in pediatric patients post-BMT, specifically in Saudi Arabia. Materials and Methods: A retrospective cohort study design was employed, involving pediatric patients who underwent BMT between January 2020 and January 2023. Clinical characteristics, laboratory results, treatment data, and outcomes were collected from electronic medical records. Logistic regression analyses were conducted to identify risk factors associated with PT. Results: Among the 77 pediatric patients in the study, no significant differences were observed in demographic characteristics, transplant types, or treatment modalities between early-onset and late-onset thrombocytopenia groups. However, the duration of thrombocytopenia post-transplant differed significantly between the groups, with early-onset cases experiencing shorter durations. Infections and graft-versus-host disease were common post-transplant complications. Chemotherapy and antiviral therapy were frequently administered treatments. Pediatric patients undergoing BMT are susceptible to PT, with varying durations based on the onset timing. Conclusion: The study emphasizes the importance of risk assessment and tailored management to mitigate thrombocytopenia in pediatric BMT patients. Further research is needed to elucidate the underlying mechanisms and optimize therapeutic interventions for thrombocytopenia in this population.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Kanan, M., Almotairi, A., Alrumaih, F., Hammad, R., & Almotairi, M. (2025). Clinical Characteristics and Risk Factors for Persistent Thrombocytopenia among Pediatric Patients after Bone Marrow Transplant in Saudi Arabia: A 3-Year Retrospective Observational Analysis from Tertiary Hospital. Journal of Pharmacology and Pharmacotherapeutics, 16(2), 214–225. https://doi.org/10.1177/0976500X241303618